Featured Research

from universities, journals, and other organizations

Fox Chase Cancer Center Researchers Identify Novel Target For Detecting Ovarian Cancer In Blood

Date:
September 15, 2004
Source:
Fox Chase Cancer Center
Summary:
Fox Chase Cancer Center researchers have found a new way to detect ovarian cancer in the blood. Reported in the Sept. 15, 2004, issue of Cancer Research, the new method targets hypermethylation--one mechanism used by cancer cells to turn off genes that protect against tumor development.

PHILADELPHIA (September 10, 2004) -- Fox Chase Cancer Center researchers have found a new way to detect ovarian cancer in the blood. Reported in the Sept. 15, 2004, issue of Cancer Research, the new method targets hypermethylation--one mechanism used by cancer cells to turn off genes that protect against tumor development.

When these tumor-suppressor genes are inactivated by hypermethylation, they cannot do their job, which then allows cancer cells to develop. This research marks the first time hypermethylation has been examined for the detection of ovarian cancer.

Fox Chase molecular biologist Paul Cairns, Ph.D., and his colleagues tested for hypermethylation of BRCA1 and RASSF1A, two genes strongly associated with ovarian cancer.

"In normal cells, BRCA1 and RASSF1A are unmethylated, meaning they are able to do their job. We found these genes to be frequently hypermethylated in the blood and peritoneal fluid from patients with ovarian cancer," explained Cairns.

Tumor samples, preoperative blood and peritoneal fluid DNA were obtained and matched from 50 patients with ovarian or primary peritoneal cancer. The blood from 20 healthy age-matched women, normal ovary tissue from 10 women, and tissue, blood and peritoneal fluid from 10 women with benign ovarian cysts were used for controls.

Thirty-four of the 50 tumors (68 percent) showed hypermethylation of one or both genes. The remaining 16 tumor samples, which did not show hypermethylation for RASSF1A or BRCA1, had hypermethylated forms of other tumor-suppressor genes: APC, p14, p16 and DAP (death-associated protein-kinases), which provided a target for screening.

An identical pattern of gene hypermethylation was found in the matched blood DNA from 41 of 50 patients (82 percent sensitivity), including 13 of 17 cases of stage I disease. No hypermethylation was observed in the non-cancerous tissue, peritoneal fluid or blood from control samples (100 percent specificity).

"We were keenly interested in the potential of hypermethylation for the detection of early ovarian tumors," said Cairns, "so we tested an additional 21 stage I tumor DNA samples." Twenty of the 21 showed hypermethylation of at least one of the six genes in the panel.

"Hypermethylation is a common event in these tumors and appears to happen relatively early because we found it in early-stage cancers," said Mitchell Edelson, M.D., a gynecological oncologist in the department of surgical oncology at Fox Chase and a co-author of the study.

"What's encouraging about this research is that there were no false-positive results. A gene negative for hypermethylation in the tumor DNA was always negative in the matched serum or peritoneal fluid DNA.

"There is no other obvious body fluid available for ovarian cancer testing except the blood," Edelson added. "In the past couple of years, we have seen detection attempts with proteomics and now with this method. It is encouraging to see so much activity regarding one of the most feared diseases for women."

The potential application of this finding could be significant because there is no reliable screening method available for ovarian cancer. Most women are diagnosed with late-stage disease after developing symptoms. The cure rate for women with advanced ovarian cancer is low, but doctors are often successful in treating early-stage disease.

"It would appear that hypermethylation is a very specific marker for this disease, and if confirmed in larger studies, methylation may be useful in ovarian cancer diagnosis," said Cairns.

In earlier research, Cairns and his colleagues have demonstrated the ability to detect prostate and kidney cancer by targeting hypermethylation.

This research was supported by a National Cancer Institute grant to Fox Chase for a Specialized Program of Research Excellence in ovarian cancer, the Pennsylvania Department of Health Ovarian Cancer Program and the Ovarian Cancer Research Fund.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Fox Chase Cancer Center Researchers Identify Novel Target For Detecting Ovarian Cancer In Blood." ScienceDaily. ScienceDaily, 15 September 2004. <www.sciencedaily.com/releases/2004/09/040915112037.htm>.
Fox Chase Cancer Center. (2004, September 15). Fox Chase Cancer Center Researchers Identify Novel Target For Detecting Ovarian Cancer In Blood. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2004/09/040915112037.htm
Fox Chase Cancer Center. "Fox Chase Cancer Center Researchers Identify Novel Target For Detecting Ovarian Cancer In Blood." ScienceDaily. www.sciencedaily.com/releases/2004/09/040915112037.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins